$103.10▼ 1.78 (1.70%)
Real-time prices · US Markets82% of 28 covering analysts have a positive rating.
weak profitability metrics drag quality score.
Quality
5.2
Health
7
Growth
5.5
Valuation
7.5
Sentiment
8.1
Analyst Target
$118.52
▲ +15.0% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
38.3×
price-to-earnings
Forward P/E
17.4×
next 12 months est.
Market Cap
$178.4B
market capitalization
Div Yield
2.44%
dividend yield
Profit Margin
9.7%
net profit margin
Gross Margin
57.1%
revenue minus COGS
ROE
—
return on equity
Beta
0.58
vs S&P 500
52-Week Range
$82 — $132
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Abbott Laboratories right now?
Abbott Laboratories's Q·Score is 6.5/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. 82% of 28 covering analysts have a positive rating. Key area to monitor: weak profitability metrics drag quality score. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for ABT?
The consensus price target for ABT is $118.52, based on ratings from 26 Wall Street analysts. This is 15.0% above the current price of $103.10. Price targets are forward-looking estimates and not guarantees of future performance.
Is ABT overvalued or undervalued?
Abbott Laboratories (ABT) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 17.4×. The consensus analyst price target of $118.52 is 15% above the current price.
What is Abbott Laboratories's profit margin?
Abbott Laboratories has a net profit margin of 9.7%, which is positive but relatively thin. Its gross margin stands at 57.1%, indicating a high-margin business model.
What is ABT's dividend yield?
Abbott Laboratories currently offers a dividend yield of 2.44%, which is above the typical market average dividend yield. Dividend yields can change based on price movements and company payout decisions.
Is Abbott Laboratories's revenue growing?
Abbott Laboratories is reporting solid revenue growth of 14.5% year-over-year. However, earnings declined 43.7%, which warrants monitoring.
How much debt does Abbott Laboratories have?
Abbott Laboratories has a debt-to-equity ratio of 0.63×, reflecting a moderate debt level, which is manageable for most profitable companies.
Compare ABT with any stock